You are here
Open
NOTE: The Solicitations and topics listed on this site are copies from the various SBIR agency solicitations and are not necessarily the latest and most up-to-date. For this reason, you should visit the respective agency SBIR sites to read the official version of the solicitations and download the appropriate forms and rules.
If no search results for your keyword(s) were found, you are encouraged to review Agency omnibus solicitations for additional funding opportunities. Omnibus solicitations are structured to be broad, extensive Programmatic issuances with research areas related to the petitioning Agency and are not limited to predetermined Topics/Subtopics. If upon reviewing you have additional questions, you may consider reaching out to the respective Agency for clarification regarding acceptable proposals (https://www.sbir.gov/agency-contacts).
-
PAR-21-057: Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)
Release Date: 11-19-2020Open Date: 01-22-2021 Due Dates: Multiple Close Date: 09-08-2023Background A biomarker is a defined characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or responses to an exposure or intervention, including therapeutic interventions. Biomarker modalities are diverse, and can include ‘omics, imaging, behavioral, digital and physiologic endpoints, as well as composite biomarkers or biomarker signatures. Becaus ...
SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health -
HC1: Analytics
Release Date: 11-22-2022Open Date: 11-22-2022 Due Dates: Multiple Close Date: 11-01-2023NA
SBIR/STTRPhase INational Science Foundation -
BT1: Animal Biotechnology
Release Date: 11-22-2022Open Date: 11-22-2022 Due Dates: Multiple Close Date: 11-01-2023NA
SBIR/STTRPhase INational Science Foundation -
AI: Artificial Intelligence (AI)
Release Date: 11-22-2022Open Date: 11-22-2022 Due Dates: Multiple Close Date: 11-01-2023The Artificial Intelligence topic focuses on innovations in the field of artificial intelligence (AI), which refers to intelligence exhibited by machines or software. AI is not a specific technology or technical method – it is instead a field of study aimed at achieving machine-based intelligence. These subtopic areas are meant to serve as examples; all proposals with technical innovation and si ...
SBIR/STTRPhase INational Science Foundation -
LC1: Asynchronous and Remote Learning
Release Date: 11-22-2022Open Date: 11-22-2022 Due Dates: Multiple Close Date: 11-01-2023NA
SBIR/STTRPhase INational Science Foundation -
AV1: Audio Augmentation and Interfaces
Release Date: 11-22-2022Open Date: 11-22-2022 Due Dates: Multiple Close Date: 11-01-2023NA
SBIR/STTRPhase INational Science Foundation -
AV: Augmented and Virtual Reality (AV)
Release Date: 11-22-2022Open Date: 11-22-2022 Due Dates: Multiple Close Date: 11-01-2023The Augmented and Virtual Reality topic aims to support the early-stage development of technological innovations in the hardware, software, photonics, displays, communication processes and other enabling technologies. Additionally, innovations that bring evidence-based academic discoveries to the public sphere via augmented and virtual reality technologies are also appropriate. Since augmented and ...
SBIR/STTRPhase INational Science Foundation -
DL1: Autonomous Systems and Economies, and Smart Contracts
Release Date: 11-22-2022Open Date: 11-22-2022 Due Dates: Multiple Close Date: 11-01-2023NA
SBIR/STTRPhase INational Science Foundation -
RFA-TR-22-029: Basket Clinical Trials of Drugs Targeting Shared Molecular Etiologies in Multiple Rare Diseases (U44 Clinical Trial Required)
Release Date: 07-13-2022Open Date: 07-18-2022 Due Dates: Multiple Close Date: 07-13-2023A. Overview While there are thousands of rare diseases, the number of underlying etiologies is much smaller. Moreover, many disease etiologies underlie multiple traditional diseases. This is most readily seen for rare monogenic diseases, where the most common etiologies include premature termination codons, protein misfolding, and abnormal RNA splicing. Other examples of rare disease shared molec ...
SBIRPhase IIDepartment of Health and Human ServicesNational Institutes of Health -
MO1: Behavioral
Release Date: 11-22-2022Open Date: 11-22-2022 Due Dates: Multiple Close Date: 11-01-2023NA
SBIR/STTRPhase INational Science Foundation